We use a Google Analytics cookie to gather anonymous information about how our site is used.
If you continue using our site we'll assume that you are happy for the use of this cookie to continue.
Speak with one of our advisors: 0800 085 6663 or
 

Prof Gordon Wishart, Chief Medical Officer at Check4Cancer to feature on Cambridge TV discussing PREDICT algorithm for new ONCOassist app

ONCOassist app adds PREDICT algorithm, licensed from Cambridge Enterprise, to help doctors make critical treatment decisions following breast cancer surgery

Chief Medical Officer at Check4Cancer, Prof Gordon Wishart led a team of clinicians and scientists to develop the PREDICT survival and treatment benefit model.

 

The PREDICT breast treatment tool, designed to help doctors determine the ideal course of treatment following a patients’ breast cancer surgery, is now available to oncology healthcare professionals globally via ONCOassist, an interactive, clinical decision support app. 

A mathematical model designed for patients and doctors to help them decide on the ideal course of treatment following breast cancer surgery, PREDICT was developed by a partnership among The Breast Unit at Cambridge University Hospitals NHS Trust (CUH), the University of Cambridge Department of Oncology and the NHS Eastern Cancer Registry and Information Centre (ECRIC). The technology was licensed to ONCOassist by Cambridge Enterprise, the commercialisation arm of the University of Cambridge.


PREDICT is the first breast cancer model of this type to include tumour HER2 and KI67 status in its decision making algorithm.

Making the PREDICT tool available through ONCOassist expands the tool’s reach to a global audience. It is available both on desktop and mobile devices (iOS and Android) in an easy-to-use and interactive format.

ONCOassist also includes adjuvant decision support calculators for other cancers, useful formulas, prognostic algorithms, American Joint Cancer Committee (AJCC) staging and Common Toxicity Criteria for Adverse Events (CTCAE) tools.

ONCOassist is used widely, around the world, and is offered as a member benefit by the European Society of Medical Oncology. It is one of the few medical apps on the market to have CE approval, meaning it is fully compliant with EU medical device standards.

ONCOassist Chief Medical Officer Dr Richard Bambury said: “The addition of the PREDICT breast algorithm will enhance our platform with new functionality to help clinicians make informed decisions about adjuvant treatment following breast cancer surgery. This will be of huge benefit to our global userbase.”

Professor Paul Pharoah, of the University of Cambridge, who was part of the development team, said: “PREDICT is used by cancer doctors from around the world.  We hope that including the model in OncoAssist will encourage more doctors to use the model and help improve outcomes for breast cancer patients.”


About ONCOassist

ONCOassist is a clinical decision support app for oncology professionals. It contains all the clinical tools oncology professionals need in an easy to use and interactive format. It is endorsed as a member benefit by the European Society of Medical Oncology and has rapidly growing global userbase. ONCOassist was found in 2012 by Kevin Bambury, Eoin O’Carroll and Dr Richard Bambury.

About PREDICT

PREDICT is a mathematical model designed for patients and doctors to help them decide on the ideal course of treatment following breast cancer surgery. It is the first model of its type to include tumour HER2 and KI67 status.

PREDICT was developed by a partnership among The Breast Unit at Cambridge University Hospitals NHS Trust (CUH), the University of Cambridge Department of Oncology and the NHS Eastern Cancer Registry and Information Centre (ECRIC).

About Cambridge Enterprise

Cambridge Enterprise Limited is a wholly owned subsidiary of the University of Cambridge, responsible for the commercialisation of University intellectual property. Activities include management and licensing of intellectual property and patents, proof of concept funding and support for University staff and research groups wishing to provide expert advice or facilities to public and private sector organisations. Cambridge Enterprise provides access to angel and early stage capital through the Cambridge Enterprise Seed Funds, University of Cambridge Enterprise Funds, Cambridge Innovation Capital and Cambridge Enterprise Venture Partners, and offers business planning, mentoring, and other related programmes.

© 2019 Check4Cancer, 1 The Mill, Copley Hill Business Park, Cambridge Road, Cambridge CB22 3GN
Registered in England and Wales. Company registration number 08866941